Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bernard Dubray

Showing results (21-30 of 50) with videos related to

Pageof 5
Sort By:
Leukemia & Lymphoma|August 3, 2002
Clinical efficacy of irradiation in CLL patients: predictive value of in vitro radio-induced apoptosisDidier Decaudin, Jozo Delic, Janine Dumont, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|November 9, 2010
Simultaneous positron emission tomography (PET) assessment of metabolism with ¹⁸F-fluoro-2-deoxy-d-glucose (FDG), proliferation with ¹⁸F-fluoro-thymidine (FLT), and hypoxia with ¹⁸fluoro-misonidazole (F-miso) before and during radiotherapy in patients with non-small-cell lung cancer (NSCLC): a pilot studyPierre Vera, Pierre Bohn, Agathe Edet-Sanson, et al.
The Journal of Surgical Research|February 9, 2024
Kidney Transplantation Anastomotic Time Is Jointly Associated With Resident and Attending ExperienceCaroline M Godfrey, Laura A Rausch, Irene D Feurer, et al.
Radiation Oncology (London, England)|October 25, 2018
FDG and FMISO PET-guided dose escalation with intensity-modulated radiotherapy in lung cancerSébastien Thureau, Bernard Dubray, Romain Modzelewski, et al.
Radiation Oncology (London, England)|May 24, 2020
Prognostic value of sarcopenia in patients treated by Radiochemotherapy for locally advanced oesophageal cancerRomain Mallet, Romain Modzelewski, Justine Lequesne, et al.
European Journal of Nuclear Medicine and Molecular Imaging|March 15, 2019
Radiotherapy boost in patients with hypoxic lesions identified by <sup>18</sup>F-FMISO PET/CT in non-small-cell lung carcinoma: can we expect a better survival outcome without toxicity? [RTEP5 long-term follow-up]Pierre Vera, Sorina-Dana Mihailescu, Justine Lequesne, et al.
BMC Cancer|February 5, 2021
Efficacy of extracranial stereotactic body radiation therapy (SBRT) added to standard treatment in patients with solid tumors (breast, prostate and non-small cell lung cancer) with up to 3 bone-only metastases: study protocol for a randomised phase III trial (STEREO-OS)Sébastien Thureau, Vincent Marchesi, Marie-Hélène Vieillard, et al.
EJNMMI Research|March 8, 2014
Monitoring tumour response during chemo-radiotherapy: a parametric method using FDG-PET/CT images in patients with oesophageal cancerPierre Vera, Bernard Dubray, Odré Palie, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|September 25, 2008
A qualitative and a quantitative analysis of an auto-segmentation module for prostate cancerDominique P Huyskens, Philippe Maingon, Luc Vanuytsel, et al.
International Journal of Radiation Oncology, Biology, Physics|July 19, 2014
Random forests to predict rectal toxicity following prostate cancer radiation therapyJuan D Ospina, Jian Zhu, Ciprian Chira, et al.
Pageof 5

Showing results (21-30 of 50) with videos related to

Sort By:
Pageof 5
Leukemia & Lymphoma|August 3, 2002
Clinical efficacy of irradiation in CLL patients: predictive value of in vitro radio-induced apoptosisDidier Decaudin, Jozo Delic, Janine Dumont, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|November 9, 2010
Simultaneous positron emission tomography (PET) assessment of metabolism with ¹⁸F-fluoro-2-deoxy-d-glucose (FDG), proliferation with ¹⁸F-fluoro-thymidine (FLT), and hypoxia with ¹⁸fluoro-misonidazole (F-miso) before and during radiotherapy in patients with non-small-cell lung cancer (NSCLC): a pilot studyPierre Vera, Pierre Bohn, Agathe Edet-Sanson, et al.
The Journal of Surgical Research|February 9, 2024
Kidney Transplantation Anastomotic Time Is Jointly Associated With Resident and Attending ExperienceCaroline M Godfrey, Laura A Rausch, Irene D Feurer, et al.
Radiation Oncology (London, England)|October 25, 2018
FDG and FMISO PET-guided dose escalation with intensity-modulated radiotherapy in lung cancerSébastien Thureau, Bernard Dubray, Romain Modzelewski, et al.
Radiation Oncology (London, England)|May 24, 2020
Prognostic value of sarcopenia in patients treated by Radiochemotherapy for locally advanced oesophageal cancerRomain Mallet, Romain Modzelewski, Justine Lequesne, et al.
European Journal of Nuclear Medicine and Molecular Imaging|March 15, 2019
Radiotherapy boost in patients with hypoxic lesions identified by <sup>18</sup>F-FMISO PET/CT in non-small-cell lung carcinoma: can we expect a better survival outcome without toxicity? [RTEP5 long-term follow-up]Pierre Vera, Sorina-Dana Mihailescu, Justine Lequesne, et al.
BMC Cancer|February 5, 2021
Efficacy of extracranial stereotactic body radiation therapy (SBRT) added to standard treatment in patients with solid tumors (breast, prostate and non-small cell lung cancer) with up to 3 bone-only metastases: study protocol for a randomised phase III trial (STEREO-OS)Sébastien Thureau, Vincent Marchesi, Marie-Hélène Vieillard, et al.
EJNMMI Research|March 8, 2014
Monitoring tumour response during chemo-radiotherapy: a parametric method using FDG-PET/CT images in patients with oesophageal cancerPierre Vera, Bernard Dubray, Odré Palie, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|September 25, 2008
A qualitative and a quantitative analysis of an auto-segmentation module for prostate cancerDominique P Huyskens, Philippe Maingon, Luc Vanuytsel, et al.
International Journal of Radiation Oncology, Biology, Physics|July 19, 2014
Random forests to predict rectal toxicity following prostate cancer radiation therapyJuan D Ospina, Jian Zhu, Ciprian Chira, et al.
Pageof 5